Y. Tanaka

发表

Impact of Arterial Access Route on Bleeding Complications in Japanese Patients Undergoing Percutaneous Coronary Intervention- Insight From the PRASFIT Trial.

S. Saito, Takeshi Kimura, H. Ogawa, 2015, Circulation journal : official journal of the Japanese Circulation Society.

Risk of bleeding and repeated bleeding events in prasugrel-treated patients: a review of data from the Japanese PRASFIT studies

S. Saito, Takeshi Kimura, H. Ogawa, 2017, Cardiovascular Intervention and Therapeutics.

Re-evaluation of Bleeding Events in the Japanese PRASFIT-Elective andPRASFIT-ACS Clinical Trials using the Bleeding Academic ResearchConsortium Criteria

S. Saito, Takeshi Kimura, H. Ogawa, 2015 .

Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.

S. Saito, K. Kitagawa, Takeshi Kimura, 2016, Journal of cardiology.

Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study

R. Nishimura, U. Broedl, A. Salsali, 2015, Cardiovascular Diabetology.

Effect of Empagliflozin on Free Fatty Acids and Ketone Bodies in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial

R. Nishimura, A. Salsali, S. Kaspers, 2019, Advances in Therapy.

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus.

K. Ueki, U. Broedl, H. Woerle, 2014, Clinical therapeutics.

Medication-taking behavior in hypertensive patients with a single-tablet, fixed-dose combination in Japan

Y. Okutani, I. Saito, T. Kushiro, 2016, Clinical and experimental hypertension.

Linagliptin as add‐on to empagliflozin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two‐part, randomized, placebo‐controlled trial

M. Haneda, J. George, K. Kaku, 2018, Diabetes, obesity & metabolism.

POS0190 EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM TWO RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDIES

T. Dörner, M. Mosca, I. de la Torre, 2022, Annals of the Rheumatic Diseases.

Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial

E. Araki, W. Sakamoto, Yuko Tanaka, 2019, Advances in Therapy.